nach oben

Journal of Neuro-Oncology

Erschienen in:

10.09.2019 | Laboratory Investigation

Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas

verfasst von: Chongxian Hou, Yukitomo Ishi, Hiroaki Motegi, Michinari Okamoto, Yafei Ou, Jiawei Chen, Shigeru Yamaguchi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Overexpression of CD44 has been detected in many types of tumor tissues. Moreover, CD44 is recognized as a cancer stem cell marker for many cancers. However, the prognostic value of CD44 for glioma patients has not yet been clarified. The authors tried to explore the impact of CD44 expression on grade II/III glioma patients.

Methods

To assess the RNA expression levels of CD44 in glioma tissues and normal brain tissues, meta-analyses were conducted in the online Oncomine database. The mRNA expression levels of CD44, CD44s, and CD44v2–v10 in 112 grade II/III glioma patients in Hokkaido University Hospital (HUH) were detected by qPCR. The RNA-seq data and clinical data of grade II/III glioma patients were obtained from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases.

Results

Based on the Oncomine database, CD44 has significantly high expression in glioma tissues as compared with normal tissues. We explored the clinical relevance of CD44 mRNA expression based on the HUH cohorts, the TCGA cohorts, and the CGGA cohorts. In survival analysis, high mRNA expression of CD44 was correlated with poor overall survival and poor progression-free survival in grade II/III glioma patients. Multivariate Cox regression analyses confirmed CD44 as an independent prognostic factor for grade II/III glioma patients.

Conclusions

The present study suggests that overexpression of CD44 is associated with a poor prognosis for grade II/III glioma patients. Moreover, our findings suggest that CD44 could serve as a prognostic biomarker in grade II/III glioma patients.

Nur mit Berechtigung zugänglich

Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:iv1–iv86. https://doi.org/10.1093/neuonc/noy131 CrossRefPubMedPubMedCentral

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS (2015) The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 15:741–752. https://doi.org/10.1586/14737175.2015.1051968 CrossRefPubMedPubMedCentral

Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45. https://doi.org/10.1038/nrm1004 CrossRefPubMed

Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4:528–539. https://doi.org/10.1038/nrc1391 CrossRefPubMed

Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI (2008) Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 18:288–295. https://doi.org/10.1016/j.semcancer.2008.03.005 CrossRefPubMed

Prochazka L, Tesarik R, Turanek J (2014) Regulation of alternative splicing of CD44 in cancer. Cell Signal 26:2234–2239. https://doi.org/10.1016/j.cellsig.2014.07.011 CrossRefPubMed

Chen C, Zhao S, Karnad A, Freeman JW (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64. https://doi.org/10.1186/s13045-018-0605-5 CrossRefPubMedPubMedCentral

Dosio F, Arpicco S, Stella B, Fattal E (2016) Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 97:204–236. https://doi.org/10.1016/j.addr.2015.11.011 CrossRefPubMed

10.

Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA, Prieto-Sanchez RM, Barba I, Martinez-Saez E, Prudkin L, Cuartas I, Raventos C, Martinez-Ricarte F, Poca MA, Garcia-Dorado D, Lahn MM, Yingling JM, Rodon J, Sahuquillo J, Baselga J, Seoane J (2010) TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655–668. https://doi.org/10.1016/j.ccr.2010.10.023 CrossRefPubMed

11.

Wang F, Zheng Z, Guan J, Qi D, Zhou S, Shen X, Wang F, Wenkert D, Kirmani B, Solouki T, Fonkem E, Wong ET, Huang JH, Wu E (2018) Identification of a panel of genes as a prognostic biomarker for glioblastoma. EBioMedicine 37:68–77. https://doi.org/10.1016/j.ebiom.2018.10.024 CrossRefPubMedPubMedCentral

12.

Nishikawa M, Inoue A, Ohnishi T, Kohno S, Ohue S, Matsumoto S, Suehiro S, Yamashita D, Ozaki S, Watanabe H, Yano H, Takahashi H, Kitazawa R, Tanaka J, Kunieda T (2018) Significance of glioma stem-like cells in the tumor periphery that express high levels of CD44 in tumor invasion, early progression, and poor prognosis in glioblastoma. Stem Cells Int 2018:5387041. https://doi.org/10.1155/2018/5387041 CrossRefPubMedPubMedCentral

13.

Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke H, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346. https://doi.org/10.1016/j.ccr.2013.08.001 CrossRefPubMed

14.

Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I (2011) CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 6:e24217. https://doi.org/10.1371/journal.pone.0024217 CrossRefPubMedPubMedCentral

15.

Pietras A, Katz AM, Ekstrom EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC (2014) Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14:357–369. https://doi.org/10.1016/j.stem.2014.01.005 CrossRefPubMedPubMedCentral

16.

Tsidulko AY, Kazanskaya GM, Kostromskaya DV, Aidagulova SV, Kiselev RS, Volkov AM, Kobozev VV, Gaitan AS, Krivoshapkin AL, Grigorieva EV (2017) Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma. Tumour Biol 39:1010428317724282. https://doi.org/10.1177/1010428317724282 CrossRefPubMed

17.

Ranuncolo SM, Ladeda V, Specterman S, Varela M, Lastiri J, Morandi A, Matos E, Bal de Kier Joffe E, Puricelli L, Pallotta MG (2002) CD44 expression in human gliomas. J Surg Oncol 79:30–35; discussion 35–36

18.

Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, Pai PC, Shin JW (2010) Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res 30:253–259PubMed

19.

Klank RL, Decker Grunke SA, Bangasser BL, Forster CL, Price MA, Odde TJ, SantaCruz KS, Rosenfeld SS, Canoll P, Turley EA, McCarthy JB, Ohlfest JR, Odde DJ (2017) Biphasic dependence of glioma survival and cell migration on CD44 expression level. Cell Rep 18:23–31. https://doi.org/10.1016/j.celrep.2016.12.024 CrossRefPubMedPubMedCentral

20.

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. https://doi.org/10.1038/nature03128 CrossRefPubMed

21.

Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021. https://doi.org/10.1158/0008-5472.CAN-04-1364 CrossRefPubMed

22.

Yan Y, Zuo X, Wei D (2015) Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med 4:1033–1043. https://doi.org/10.5966/sctm.2015-0048 CrossRefPubMedPubMedCentral

23.

Brown DV, Daniel PM, D’Abaco GM, Gogos A, Ng W, Morokoff AP, Mantamadiotis T (2015) Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Oncotarget 6:6267–6280. https://doi.org/10.18632/oncotarget.3365 CrossRefPubMedPubMedCentral

24.

Brown DV, Filiz G, Daniel PM, Hollande F, Dworkin S, Amiridis S, Kountouri N, Ng W, Morokoff AP, Mantamadiotis T (2017) Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity. PLoS ONE 12:e0172791. https://doi.org/10.1371/journal.pone.0172791 CrossRefPubMedPubMedCentral

25.

Tanaka S, Nakada M, Yamada D, Nakano I, Todo T, Ino Y, Hoshii T, Tadokoro Y, Ohta K, Ali MA, Hayashi Y, Hamada J, Hirao A (2015) Strong therapeutic potential of gamma-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells. J Neurooncol 121:239–250. https://doi.org/10.1007/s11060-014-1630-z CrossRefPubMed

26.

Wang HH, Liao CC, Chow NH, Huang LL, Chuang JI, Wei KC, Shin JW (2017) Whether CD44 is an applicable marker for glioma stem cells. Am J Transl Res 9:4785–4806PubMedPubMedCentral

27.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262 CrossRefPubMed

28.

Miwa T, Nagata T, Kojima H, Sekine S, Okumura T (2017) Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer. Int J Oncol 51:771–780. https://doi.org/10.3892/ijo.2017.4063 CrossRefPubMedPubMedCentral

29.

Kaaijk P, Troost D, Morsink F, Keehnen RM, Leenstra S, Bosch DA, Pals ST (1995) Expression of CD44 splice variants in human primary brain tumors. J Neurooncol 26:185–190CrossRefPubMed

30.

Ariza A, Lopez D, Mate JL, Isamat M, Musulen E, Pujol M, Ley A, Navas-Palacios JJ (1995) Role of CD44 in the invasiveness of glioblastoma multiforme and the noninvasiveness of meningioma: an immunohistochemistry study. Hum Pathol 26:1144–1147CrossRefPubMed

31.

Ylagan LR, Quinn B (1997) CD44 expression in astrocytic tumors. Mod Pathol 10:1239–1246PubMed

32.

Resnick DK, Resnick NM, Welch WC, Cooper DL (1999) Differential expressions of CD44 variants in tumors affecting the central nervous system. Mol Diagn 4: 219–232. 10.154/MODI00400219CrossRefPubMed

33.

Li H, Hamou MF, de Tribolet N, Jaufeerally R, Hofmann M, Diserens AC, Van Meir EG (1993) Variant CD44 adhesion molecules are expressed in human brain metastases but not in glioblastomas. Cancer Res 53:5345–5349PubMed

34.

Li H, Liu J, Hofmann M (1995) CD44 expression patterns in primary and secondary brain tumors. Zhonghua Yi Xue Za Zhi 75(525–528):573

35.

Dajon M, Iribarren K, Cremer I (2017) Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. Immunobiology 222:89–100. https://doi.org/10.1016/j.imbio.2016.06.009 CrossRefPubMed

36.

Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu K, Wu A (2010) TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 10:415. https://doi.org/10.1186/1471-2407-10-415 CrossRefPubMedPubMedCentral

37.

Li C, Ma L, Liu Y, Li Z, Wang Q, Chen Z, Geng X, Han X, Sun J, Li Z (2019) TLR2 promotes development and progression of human glioma via enhancing autophagy. Gene 700:52–59. https://doi.org/10.1016/j.gene.2019.02.084 CrossRefPubMed

38.

Jiang Y, Zhou J, Luo P, Gao H, Ma Y, Chen YS, Li L, Zou D, Zhang Y, Jing Z (2018) Prosaposin promotes the proliferation and tumorigenesis of glioma through toll-like receptor 4 (TLR4)-mediated NF-kappaB signaling pathway. EBioMedicine 37:78–90. https://doi.org/10.1016/j.ebiom.2018.10.053 CrossRefPubMedPubMedCentral

39.

Qadri M, Almadani S, Jay GD, Elsaid KA (2018) Role of CD44 in regulating TLR2 activation of human macrophages and downstream expression of proinflammatory cytokines. J Immunol 200:758–767. https://doi.org/10.4049/jimmunol.1700713 CrossRefPubMed

40.

Svitkina TM (2018) Ultrastructure of the actin cytoskeleton. Curr Opin Cell Biol 54:1–8. https://doi.org/10.1016/j.ceb.2018.02.007 CrossRefPubMedPubMedCentral

41.

Hohmann T, Dehghani F (2019) The cytoskeleton—a complex interacting meshwork. Cells. https://doi.org/10.3390/cells8040362 CrossRefPubMedPubMedCentral

42.

Zagzag D, Friedlander DR, Margolis B, Grumet M, Semenza GL, Zhong H, Simons JW, Holash J, Wiegand SJ, Yancopoulos GD (2000) Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 33:49–55. https://doi.org/10.1159/000028975 CrossRefPubMed

43.

Kwiatkowska A, Didier S, Fortin S, Chuang Y, White T, Berens ME, Rushing E, Eschbacher J, Tran NL, Chan A, Symons M (2012) The small GTPase RhoG mediates glioblastoma cell invasion. Mol Cancer 11:65. https://doi.org/10.1186/1476-4598-11-65 CrossRefPubMedPubMedCentral

44.

Bourguignon LY (2008) Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol 18:251–259. https://doi.org/10.1016/j.semcancer.2008.03.007 CrossRefPubMedPubMedCentral

45.

Chow MT, Luster AD (2014) Chemokines in cancer. Cancer. Immunol Res 2:1125–1131. https://doi.org/10.1158/2326-6066.CIR-14-0160 CrossRef

46.

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205 CrossRefPubMed

47.

Sciume G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G (2010) CX3CR47/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. Neuro Oncol 12:701–710. https://doi.org/10.1093/neuonc/nop076 CrossRefPubMedPubMedCentral

48.

Ehtesham M, Winston JA, Kabos P, Thompson RC (2006) CXCR48 expression mediates glioma cell invasiveness. Oncogene 25:2801–2806. https://doi.org/10.1038/sj.onc.1209302 CrossRefPubMed

49.

Zhang J, Sarkar S, Yong VW (2005) The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. Carcinogenesis 26:2069–2077. https://doi.org/10.1093/carcin/bgi183 CrossRefPubMed

50.

Tang W, Wang X, Chen Y, Zhang J, Chen Y, Lin Z (2015) CXCL12 and CXCR50 as predictive biomarkers of glioma recurrence pattern after total resection. Pathol Biol 63:190–198. https://doi.org/10.1016/j.patbio.2015.07.002 CrossRefPubMed

Titel: Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas
verfasst von: Chongxian Hou
Yukitomo Ishi
Hiroaki Motegi
Michinari Okamoto
Yafei Ou
Jiawei Chen
Shigeru Yamaguchi
Publikationsdatum: 10.09.2019
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03288-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway

Safety and efficacy of repeat radiosurgery for acromegaly: an International Multi-Institutional Study

Treatment strategies for glioblastoma in older patients: age is just a number

Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging

Underweight and weight loss are predictors of poor outcome in patients with brain metastasis